140695-85-8

Basic information

• Product Name: (R)-1-Boc-3-(hyroxymethyl)piperidine
• Synonyms: (R)-tert-butyl 3-(hydroxyMethyl)piperidin-1-carboxylate;tert-butyl (3R)-3-(hydroxyMethyl)piperidine-1-carboxylate;BOC-R-PIP-3MEOH;3-(R)-N-BOC-PIPERIDINE METHANOL;N-BOC-(3R)-PIP(3-CH2OH);(R)-3-HYDROXYMETHYL-PIPERIDINE-1-CARBOXYLIC ACID TERT-BUTYL ESTER;(R)-1-N-BOC-3-(HYDROXYMETHYL)PIPERIDINE;(R)-1-BOC-3-(HYDROXYMETHYL)PIPERIDINE
• CAS NO: 140695-85-8
• Molecular Formula: C₁₁H₂₁NO₃
• Molecular Weight: 215.29
• Product Categories: piperidine
• Mol File: 140695-85-8.mol
• Article Data: 23

Chemical Properties

• Melting Point: 77-81 °C
• Boiling Point: 308 °C at 760 mmHg
• Flash Point: 140.1 °C
• Appearance: White to yellow/Powder
• Density: 1.059 g/cm³
• Storage Temp.: 2-8°C
• PKA: 14.93±0.10(Predicted)
• Water Solubility: Slightly soluble in water.
• CAS DataBase Reference: (R)-1-Boc-3-(hyroxymethyl)piperidine(CAS DataBase Reference)
• NIST Chemistry Reference: (R)-1-Boc-3-(hyroxymethyl)piperidine(140695-85-8)
• EPA Substance Registry System: (R)-1-Boc-3-(hyroxymethyl)piperidine(140695-85-8)

Safety Data

• Hazard Codes: Xi,N,T
• Statements: 25-36-50
• Safety Statements: 26-45-61
• RIDADR: UN2811
• Hazardous Substances Data: 140695-85-8(Hazardous Substances Data)

Usage

Uses

(R)-(-)-1-Boc-3-(hydroxymethyl)piperidine is used as pharmaceutical intermediate.

Upstream product

• 24424-99-5 di-tert-butyl dicarbonate 
• 37675-20-0 (R)-3-hydroxymethyl piperidine 
• 194726-46-0 (3R)-3-formylpiperidine-1-carboxylic acid tert-butyl ester 
• 445398-78-7 N-benzyl-hepta-4(E),6-dien-1-amine 
• 651321-53-8 Benzyl-[(E)-hepta-4,6-dien-(E)-ylidene]-amine 
• 79280-39-0 (4E)-hepta-4,6-dienal 
• 33741-15-0 methyl (4E)-hepta-4,6-dienoate 
• 498-95-3 (R)-nipecotic acid 
• 140645-20-1 t-butyl (R,S)-3-<(butyryloxy)methyl>-1-piperidine-carboxylate 
• 4606-65-9 3-(hydroxymethy)piperidine 
• 108-30-5 succinic acid anhydride 
• 116574-71-1 (±)-tert-butyl 3-(hydroxymethyl)piperidine-1-carboxylate 
• 109-02-4 4-methyl-morpholine 
• 163438-09-3 (R)-1-Boc-nipecotic acid 

Downstream Products

• 191092-07-6 (R)-tert-butyl 3-((tosyloxy)methyl)piperidine-1-carboxylate 
• 158406-99-6 1,1-dimethylethyl (3S)-3-(bromomethyl)-1-piperidinecarboxylate 
• 939986-61-5 tert-butyl (3R)-3-{[(5-nitropyridin-2-yl)oxy]methyl}piperidine-1-carboxylate 
• 1393331-67-3 [18F](R)-N-(4-bromo-2-fluorophenyl)-7-((1-(2-fluoroethyl)piperidin-3-yl)methoxy)-6-methoxyquinazolin-4-amine 

Relevant articles and documents

Design and evaluation of novel piperidine HIV-1 protease inhibitors with potency against DRV-resistant variants

A novel class of HIV-1 protease inhibitors with flexible piperidine as the P2 ligand was designed with the aim of improving extensive interactions with the active subsites. Many inhibitors exhibited good to excellent inhibitory effect on enzymatic activity and viral infectivity. In particular, inhibitor 3a with (R)-piperidine-3-carboxamide as the P2 ligand and 4-methoxybenzenesulfonamide as the P2’ ligand showed an enzyme Ki value of 29 pM and antiviral IC50 value of 0.13 nM, more than six-fold enhancement of activity compared to DRV. Furthermore, there was no significant change in potency against DRV-resistant mutations and HIV-1NL4?3 variant for 3a. Besides, inhibitor 3a exhibited potent antiviral activity against subtype C variants with low nanomole EC50 values. In addition, the molecular modeling revealed important hydrogen bonds and other favorable van der Waals interactions with the backbone atoms of the protease and provided insight for designing and optimizing more potent HIV-1 protease inhibitors.

SUBSTITUTED (PIPERIDIN-1-YL)ARYL ANALOGUES FOR MODULATING AVILACTIVITY

In one aspect, the disclosure relates to compounds useful to regulate, limit, or inhibit the expression of AVIL (advillin), methods of making same, pharmaceutical compositions comprising same, and methods of treating disorders associated with AVIL dysregulation using same. In aspects, the disclosed compounds, compositions and methods are useful for treating disorders or diseases in which the regulation, limitation, or inhibition of the expression of AVIL can be clinically useful, such as, for example, the treatment of cancer. This abstract is intended as a scanning tool for purposes of searching in the particular art and is not intended to be limiting of the present disclosure.

Synthetic method for (R)-N-tert-butoxycarbonyl-3-hydroxymethylpiperidine

The invention discloses a synthetic method for (R)-N-tert-butoxycarbonyl-3-hydroxymethylpiperidine. The method comprises the following four steps: synthesizing ethyl 3-piperidinecarboxylate (compoundII), synthesizing ethyl (R)-nipecotate-L-tartarate (compound III), synthesizing ethyl (R)-N-Boc-3-piperidinecarboxylate (compound IV) and synthesizing the (R)-N-tert-butoxycarbonyl-3-hydroxymethylpiperidine (compound V); and the method comprises the following special steps: synthesizing the compound II by using 3-piperidinecarboxylic acid (compound I) as a raw material through chloroacylation andethanol esterification; performing a salt formation reaction to form the compound III; adding a Boc anhydride and performing a reaction to obtain the compound IV; and finally performing sodium borohydride reduction to obtain the compound V. The method provided by the invention has the advantages of mild reaction conditions, environmental friendliness, simple operation steps, better reproducibilityand high practicability, and is suitable for industrial mass production of the (R)-N-tert-butoxycarbonyl-3-hydroxymethylpiperidine.